Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 8/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.31 |
| ▸ | TYK2 | P29597 | 3/20 | 0.31 |
| ▸ | JAK3 | P52333 | 3/20 | 0.31 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.31 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.31 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16623464 | 0.91 | JAK1 (0.38) | JAK1JAK2TYK2JAK3PRKAA1 | |
| SCHEMBL16623542 | 0.89 | JAK1 (0.39) | JAK1JAK2 | |
| SCHEMBL16623488 | 0.89 | JAK1 (0.33) | JAK1JAK2TYK2JAK3PRKAA1 | |
| SCHEMBL16623512 | 0.87 | JAK1 (0.43) | JAK1JAK2TYK2JAK3PRKAA1 | |
| SCHEMBL18052613 | 0.85 | JAK1 (0.33) | JAK1JAK2TYK2JAK3PRKAA1 | |
| SCHEMBL16623567 | 0.85 | BRD4 (0.36) | JAK1 | |
| SCHEMBL16623538 | 0.84 | JAK1 (0.31) | JAK1JAK2TYK2JAK3 | |
| SCHEMBL16623581 | 0.83 | JAK2 (0.37) | JAK1JAK2TYK2JAK3PRKAA1 | |
| SCHEMBL16623501 | 0.82 | JAK1 (0.34) | JAK1 | |
| SCHEMBL16623440 | 0.81 | JAK2 (0.44) | JAK1JAK2TYK2JAK3PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | JAK1 2/4885JAK2 1/4885TYK2 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.